What's open and closed on Juneteenth 2025? Find out if banks, supermarkets and other stores are operating.

From celebrating Juneteenth to the erasure of Black history: Charles M. Blow on America today
Juneteenth has arrived, with Americans now celebrating its fifth year as a federally recognized holiday. Given its relatively new status as a federal holiday, you may be wondering whether your local stores are operating as normal.
Also known as Freedom Day or Emancipation Day, Juneteenth is celebrated on June 19 to commemorate the day in 1865 when Union soldiers arrived in Galveston, Texas to announce the Civil War was over, informing enslaved people in Texas that they were free.
The majority of businesses will remain open, but there are some exceptions — including banks and the stock market.
Read on to see what's open and closed on Thursday. And remember to check local store hours before heading over, as they may vary.
Is Walmart open on Juneteenth?
Walmart's locations are open on June 19 "unless otherwise required by state or local regulations," a company spokesperson said.
Is Target on Juneteenth?
Yes, Target is open and is operating under its normal hours, a spokesperson confirmed.
Is Costco open on Juneteenth?
Costco stores will be open, according to its holiday calendar.
Is Chick-fil-A open?
Chick-fil-A locations are generally open, although this may vary by location.
"Celebrating and observing holidays like Juneteenth is up to the discretion of the Chick-fil-A restaurant owner-operator," a spokesperson told CBS News.
Fast-food chains McDonald's and Burger King also confirmed to CBS News that they will be open on the 19th.
Is the stock market open on Juneteenth?
U.S. markets are closed on Thursday, according to the New York Stock Exchange and Nasdaq.
Is the United States Postal Service open?
The U.S. Postal Service's (USPS) retail locations are closed on June 19 and there will be no regular mail delivery, according to the postal agency. Business will resume Friday, June 20.
What about UPS and FedEx?
While USPS is not operating Thursday, Americans will still be able to send and receive packages through UPS and FedEx. Their retail locations will be open on Juneteenth and regular delivery services will be running.
Are businesses, supermarkets and fast-food chains open?
Most retailers will be open on Juneteenth. See the list below for a sampling of places that are operating.
Aldi
CVS
Dollar General
Home Depot
HomeGoods
Homesense
IKEA
Kroger
TJ Maxx
Marshalls
Sierra
Starbucks
Stop & Shop
Walgreens (majority of pharmacies will be closed)
Wegmans
Are banks open on Juneteenth?
Several banks will be closed in observance of the Juneteenth holiday, including Bank of America, Wells Fargo and J.P. Morgan Chase.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Yahoo

7 minutes ago

• Yahoo

Keller Industrial Properties to break ground on facility at Grissom Aeroplex

Keller Logistics Group announced the groundbreaking of a new 150,000-square-foot speculative warehouse at Grissom Aeroplex. Located at S. Innovation Way and West C.R. 800 South in Bunker Hill, the next-generation facility, developed in partnership with ARCO, aims to meet the surging demand for flexible, high-performance industrial space in the Peru-Bunker Hill corridor, according to a press release from ARCO. The warehouse was designed with future-proof capabilities and will feature 36-foot clear heights, multi-tenant rear-load access, and the potential to expand to 200,000 square feet. With six dock positions, three drive-in ramps, 40,000-lb airbag levelers, 800-amp power, and ESFR fire protection, it is engineered to serve a wide range of distribution, manufacturing, and logistics tenants. The ceremonial groundbreaking is set for Saturday, June 28. Completion is slated for late 2025. 'This is more than just a building—it's a long-term investment in the future of Indiana's logistics economy,' said Bryan Keller, president of Keller Industrial Properties. 'As supply chains continue shifting toward regionalized models and faster fulfillment, we're providing the infrastructure that makes those models sustainable and scalable.' The project responds directly to the trends shaping the industrial real estate market across the Midwest. According to CBRE's Q4 2024 Midwest Industrial Market Report, over 37 million square feet of industrial space was under construction across the region, with net absorption reaching 5.7 million square feet, driven by strong occupier demand and an evolving e-commerce landscape. 'The Peru-Bunker Hill corridor is one of Indiana's most compelling growth areas for logistics and manufacturing,' said Austin Brasher, vice president at ARCO. 'This project positions Keller and future tenants at the heart of that growth, offering proximity to major markets without the operational constraints of urban cores.' Local and regional leaders joined Keller and ARCO at the ceremonial groundbreaking, underscoring the project's broader economic impact. 'This development brings jobs, investment, and visibility to the region, aligning perfectly with our long-term economic goals,' said Jim Tidd, Economic Development Director with the Miami County Economic Development Authority. The project team also includes Curran Architecture of Indianapolis, which provided architectural design and renderings for the facility. The press release said the warehouse will be strategically located within a high-visibility logistics corridor, sitting near key interstates and freight corridors, enabling efficient access to regional and national markets while offering the labor force infrastructure and incentives critical to modern supply chain operations.

Yahoo

17 minutes ago

• Yahoo

Vertex Presents Positive Data for Zimislecel in Type 1 Diabetes at the American Diabetes Association 85th Scientific Sessions

– Results from the study continue to demonstrate the transformative potential of zimislecel with consistent and durable patient benefit – – All 12 patients with at least one year of follow-up who received a full dose of zimislecel as a single infusion achieved ADA-recommended target HbA1c levels <7% and >70% time-in-range (70-180 mg/dL), and 10/12 patients were insulin free – – Data presented at ADA simultaneously published in the New England Journal of Medicine – – Vertex to host investor webcast tonight, June 20, 2025, at 7:15 p.m. CT / 8:15 p.m. ET – BOSTON, June 20, 2025--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced simultaneous presentation and publication of updated data from the Phase 1/2 portion of the Phase 1/2/3 FORWARD-101 clinical trial of zimislecel (VX-880), an investigational stem cell-derived, fully differentiated islet cell therapy, in people with type 1 diabetes (T1D) with impaired hypoglycemic awareness and severe hypoglycemic events (SHEs). The data were featured in an oral presentation at the American Diabetes Association (ADA) annual conference in Chicago as part of the symposium, "Innovation and Progress in Stem Cell-Derived Islet-Cell Replacement Therapy," from 6:15-6:30 p.m. CT (abstract 2025-A-1921) and published online by the New England Journal of Medicine. The data are from 12 patients who received the full dose of zimislecel as a single infusion and were followed for at least one year, as of October 2024. Results from the study to date continue to demonstrate the transformative potential of zimislecel with consistent and durable patient benefit with longer follow-up. All 12 participants: Demonstrated engraftment with glucose-responsive endogenous C-peptide production, which was durable through one year of follow-up. Achieved the ADA targets of HbA1c <7% and time in range of >70%. Were free of SHEs from day 90 onwards. Had a reduction in exogenous insulin use (mean reduction in daily insulin dose: 92%). 10/12 (83%) no longer required exogenous insulin at Month 12. Achieved the Phase 1/2 primary endpoint of elimination of SHEs with HbA1c <7%. Zimislecel continues to be generally well tolerated. Most adverse events (AEs) were mild or moderate, and there were no serious AEs related to zimislecel treatment. As previously reported, two patient deaths occurred, both unrelated to treatment with zimislecel. The safety profile is generally consistent with the immunosuppressive regimen used in the study, the infusion procedure, and complications from long-standing diabetes. "These data on the first fully differentiated, stem cell-derived, off-the-shelf islet cell therapy continue to be unprecedented. The magnitude, consistency and durability of the results from all 12 patients with more than one year of follow-up reinforce the transformative potential of zimislecel for people living with T1D complicated by severe hypoglycemia," said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer at Vertex. "We are excited to complete enrollment and dosing in the Phase 1/2/3 Program and look forward to potential regulatory submissions next year." "It's remarkable to see 12 out of 12 patients with baseline HbA1c above 7% and multiple severe hypoglycemic events reach consensus targets for glycemic control by both HbA1c and time in range as well as elimination of severe hypoglycemic events," said Michael R. Rickels, M.D., M.S., Medical Director, Pancreatic Islet Cell Transplant Program, Willard and Rhoda Ware Professor in Diabetes and Metabolic Diseases, Presenting Author and Steering Committee Co-Chair for the zimislecel clinical program, and author on the New England Journal of Medicine paper. "As I think about my patients and the unmet need in the type 1 diabetes community, the results we've seen so far for restoring endogenous insulin secretion with a stem cell-derived islet therapy bring me hope and confidence for a transformative treatment option for individuals with type 1 diabetes in the not-so-distant future." About Type 1 DiabetesT1D results from the autoimmune destruction of insulin-producing beta cells in pancreatic islets. Insulin deficiency results in hyperglycemia and can lead to acute life-threatening complications such as diabetic ketoacidosis. People with T1D are reliant on lifelong treatment with exogenous insulin that requires careful monitoring of blood glucose levels. Even with the availability of advanced exogenous insulin delivery and glucose monitoring systems, people with T1D can have periods of very low and very high blood sugar levels. Exogenous insulin has a narrow therapeutic range and carries an inherent risk of causing low blood sugar levels or hypoglycemic events, which can potentially result in arrhythmias, seizures, coma and even death. Due to the limitations and complexities of exogenous insulin treatment, it can be difficult for people with T1D to achieve and maintain good glucose control. Exposure to prolonged periods of high blood glucose levels, or hyperglycemia, can lead to long-term complications such as nerve damage, kidney disease/failure, eye disease (including vision loss), cardiovascular disease, stroke and even death. HbA1c is a measure of average blood glucose over the most recent ~2-3 months, and the consensus guidance is to maintain an HbA1c of <7% to reduce the risk of long-term complications; only ~1 in 4 people with T1D globally meet this clinical target. Current standards of care do not address the underlying cause of the disease and leave people with T1D susceptible to both hypo- and hyperglycemia and their associated morbidity and mortality. There is no cure for T1D. About ZimislecelZimislecel (VX-880) is an investigational allogeneic stem cell-derived, fully differentiated, insulin-producing islet cell therapy manufactured using proprietary technology. Zimislecel is being evaluated for patients who have T1D with impaired hypoglycemic awareness and severe hypoglycemia. Zimislecel has the potential to restore the body's ability to regulate glucose levels by restoring pancreatic islet cell function, including glucose-responsive insulin production. Zimislecel is delivered by an infusion into the hepatic portal vein and requires chronic immunosuppressive therapy to protect the islet cells from immune rejection. The zimislecel trial has expanded to additional sites that are currently active and enrolling in the U.S., Canada and Europe. Zimislecel has been granted Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations from the U.S. Food and Drug Administration, Priority Medicines (PRIME) designation from the European Medicines Agency (EMA), and has secured an Innovation Passport under the Innovative Licensing and Access Pathway (ILAP) from the UK Medicines and Healthcare products Regulatory Agency (MHRA). Zimislecel is investigational and has not been approved by health authorities globally. About VertexVertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases and conditions. The company has approved therapies for cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia and acute pain, and it continues to advance clinical and research programs in these areas. Vertex also has a robust clinical pipeline of investigational therapies across a range of modalities in other serious diseases where it has deep insight into causal human biology, including neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy, primary membranous nephropathy, autosomal dominant polycystic kidney disease, type 1 diabetes and myotonic dystrophy type 1. Vertex was founded in 1989 and has its global headquarters in Boston, with international headquarters in London. Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia, Latin America and the Middle East. Vertex is consistently recognized as one of the industry's top places to work, including 15 consecutive years on Science magazine's Top Employers list and one of Fortune's 100 Best Companies to Work For. For company updates and to learn more about Vertex's history of innovation, visit or follow us on LinkedIn, Facebook, Instagram, YouTube and X. Special Note Regarding Forward-Looking StatementsThis press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, (i) statements by Carmen Bozic, M.D., and Michael R. Rickels, M.D., M.S., in this press release, (ii) plans, expectations for, and the potential benefits of zimislecel, (iii) expectations for the Phase 1/2/3 clinical trial for zimislecel, including expectations for the trial to complete enrollment and dosing, and (iv) plans for potential regulatory submissions next year. While Vertex believes the forward-looking statements contained in this press release are accurate, these forward-looking statements represent the company's beliefs only as of the date of this press release and there are a number of risks and uncertainties that could cause actual events or results to differ materially from those expressed or implied by such forward-looking statements. Those risks and uncertainties include, among other things, that data from a limited number of patients may not be indicative of final clinical trial results, that data from the company's research and development programs may not support registration or further development of its potential medicines in a timely manner, or at all, due to safety, efficacy, that timelines for regulatory submissions may be longer than anticipated, and other risks listed under the heading "Risk Factors" in Vertex's most recent annual report and subsequent quarterly reports filed with the Securities and Exchange Commission at and available through the company's website at You should not place undue reliance on these statements, or the scientific data presented. Vertex disclaims any obligation to update the information contained in this press release as new information becomes available. (VRTX-GEN) Investor Event and Webcast Vertex will host an investor event on Friday, June 20, 2025, at 7:15 p.m. CT/8:15 p.m. ET, in Chicago, to discuss the positive zimislecel data in type 1 diabetes. A live webcast of the presentation and Q&A portions can be accessed through the Investor Relations section of Vertex's website at An archived webcast will be available on the company's website. View source version on Contacts Vertex Pharmaceuticals IncorporatedInvestors: InvestorInfo@ Media: mediainfo@ orInternational: +44 20 3204 5275

Forbes

23 minutes ago

• Forbes

250 Million Acre Public Land Sale Would Ruin The Off-Road Industry

Ford Performance at the 2025 King of the Hammers in Southern California's Johnson Valley. Since President Trump took office in January, the amount of threats to anything considered public—from a large slice of our nation's workforce to the media—have been unrelenting. Earlier this month, these threats took on a new form: potentially robbing the American people of millions of acres of public land. Unveiled on June 11th and revised on the 14th, the Senate Energy and Natural Resources Committee's budget reconciliation bill outlines over 250 million acres, to be slightly more exact, that could be offered up for sale to private business. As reported on by Jonathon Klein of Ride Apart, this could have a tremendous negative impact on not just our natural resources, but every corner of the outdoor industry as well. For those amongst us who enjoy off-road driving (or hiking, camping, fishing, hunting, cycling, climbing, etc.), the possibility of being cut-off from lands where we savor such activity is very real. Klein points out one particular swath of land in Southern California, Johnson Valley—home to one of the world's top off-road racing events, King of the Hammers—is on the chopping block, which would not only be detrimental to this event, but every single industry that's involved in it. Automakers, the aftermarket performance and racing industries, tourism, general outdoor equipment industries; the list goes on. Take that same scenario and multiply it by every other parcel of land that outdoor enthusiasts could lose access to, and the damage would be extensive. For a good overall picture of what's on the chopping block, The Wilderness Society has created a handy map. Competitors at the 2020 King of the Hammers in Johnson Valley, California. But why is all of this land potentially for sale? As stated in the bill itself, as much as $15 billion in revenue could come from expanded oil, gas, coal, and geothermal leasing. Other aims include increased housing production, domestic energy security and timber production, as well as, in the bill's summarized words, 'ensuring states and counties benefit from energy projects on federal lands.' The Wilderness Society has also outlined a handful of counter arguments. In its words, 'research suggests that very little of the land managed by the BLM (Bureau of Land Management) and USFS (US Forest Service) is actually suitable for housing.' It also explains that the federal government can revoke national monument status and that certain changes would negatively impact sovereign Tribal Nations. We can't forget the fact that increased energy production carries its own environmental hazards, too. It's all bad and very unnecessary. One thing that truly makes America great is its beautiful natural land that's here for all of us to savor, and this bill could cut off a very significant portion of it. And again, there's the immense adverse effect on every single outdoor industry, especially off-road driving and racing, and the massive amount of American companies that feed it. Contact your US senator and let them know how you feel. Especially if you live in Utah, which is Senator Mike Lee's turf. He's Chairman of the Senate Committee on Energy and Natural Resources and the creator of this bill—ironically, as many as 18 million acres of his state's land could potentially be up for sale. That's a lot of territory for off-road driving, hunting, shooting, fishing, climbing, camping, hiking, mountain biking, and so on.